Artemisinin Market Size, Share, Growth, Trends, Global Industry Analysis By Type (Extraction from Artemisia Annua and Semisynthetic Artemisinin) By Application (Antimalarial Injections and Antimalarial Tablets), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

ARTEMISININ MARKET OVERVIEW

The global Artemisinin Market is estimated to be valued at approximately USD 0.12 Billion in 2026. The market is projected to reach USD 0.45 Billion by 2035, expanding at a CAGR of 15.6% from 2026 to 2035.

The Artemisinin Market is fundamentally driven by global malaria incidence exceeding 240 million cases annually, with more than 600,000 reported deaths in recent global health estimates. Over 95% of malaria cases occur in tropical and subtropical regions across 85+ endemic countries. Artemisinin-based combination therapies (ACTs) account for nearly 90% of first-line malaria treatments worldwide. Global artemisinin raw material production exceeds 200 metric tons annually, derived primarily from Artemisia annua cultivation spanning more than 200,000 hectares. The Artemisinin Market Size is closely tied to public health procurement programs, where over 70% of demand is supported by international health initiatives and government-funded distribution channels.

In the United States, the Artemisinin Market is comparatively niche, representing less than 5% of global antimalarial consumption but over 30% of research-focused artemisinin derivative trials. Approximately 2,000 malaria cases are reported annually in the U.S., with more than 95% classified as travel-related infections. The U.S. imports over 90% of its artemisinin API requirements, primarily for pharmaceutical formulation and clinical research. Around 40% of domestic demand is linked to hospital-based injectable formulations. The Artemisinin Market Analysis in the U.S. highlights that 60% of procurement occurs through federally regulated healthcare facilities and emergency infectious disease response programs.

Key Findings

Technological Advancements to Boost Market Growth

The Artemisinin Market Trends indicate that over 90% of malaria treatment protocols in endemic regions utilize artemisinin-based combination therapies. Approximately 120 million ACT treatment courses are distributed annually through global health programs. Advances in semisynthetic production have enabled up to 25% reduction in reliance on seasonal crop yields. More than 50 clinical trials involving artemisinin derivatives are ongoing globally, with 30% targeting oncology and autoimmune research applications.

In the Artemisinin Market Research Report, nearly 68% of raw artemisinin extraction remains concentrated in Asia-Pacific, particularly China and Vietnam. African cultivation of Artemisia annua has expanded by 18% since 2022, reaching over 40,000 hectares. Injectable artesunate accounts for 85% of severe malaria hospital treatments. Stability improvements in tablet formulations have extended shelf life by 24 months under controlled storage conditions below 30°C. Pediatric dosing represents 58% of distributed ACT tablets in malaria-endemic regions. The Artemisinin Market Outlook highlights that 72% of donor-funded procurement contracts specify prequalified manufacturing standards, while 46% of new facilities implemented automated extraction systems between 2023 and 2024.

• According to the World Health Organization (WHO), over 241 million malaria cases were reported globally in 2022, driving increased demand for artemisinin-based combination therapies (ACTs) in endemic countries.

• The Global Malaria Programme (WHO) reports that ACTs account for nearly 60% of anti-malarial treatments in Africa, highlighting the critical role of artemisinin derivatives in treatment protocols.

Download Free Sample to learn more about this report

ARTEMISININ MARKET SEGMENTATION

The Artemisinin Market Size is segmented by type and application, with extraction from Artemisia annua accounting for 72% of supply and semisynthetic production holding 28%. By application, antimalarial tablets dominate with 65% share, while injections account for 35%. Over 90% of distributed doses are part of ACT regimens. Nearly 80% of malaria cases occur in rural settings, influencing oral tablet preference. Injectable forms are primarily utilized in hospital settings representing 40% of severe case treatments.

By Type

As per type, the market is classified into Extraction from Artemisia Annua and Semisynthetic Artemisinin.

• Extraction From Artemisia Annua: This segment represents 72% of global supply. Artemisia annua cultivation spans over 200,000 hectares worldwide. Average artemisinin yield per hectare ranges between 25 kg and 40 kg depending on agronomic practices. China contributes nearly 55% of extracted artemisinin, while Vietnam accounts for 15%. Approximately 65% of extraction facilities operate solvent-based isolation systems. Seasonal harvest cycles occur 1 to 2 times annually in tropical climates. Around 70% of bulk API production depends on agricultural output consistency. Approximately 45% of cultivated acreage is concentrated in 5 major provinces in China with altitude ranges between 500 and 1,500 meters above sea level. Around 30% of global leaf biomass undergoes ethanol-based extraction processes achieving purity levels above 98%. Nearly 22% of farmers have adopted high-yield hybrid seed varieties capable of increasing artemisinin concentration by 15% compared to traditional strains.

• Semisynthetic Artemisinin: Semisynthetic artemisinin holds 28% share and relies on engineered yeast fermentation processes. Production capacity expanded by 27% between 2023 and 2024. Fermentation yields reach up to 25 g/L under optimized conditions. Nearly 40% of new manufacturing investments focus on semisynthetic facilities. This method reduces agricultural dependency by 30%. Approximately 50% of biotechnology-driven producers are located in North America and Europe. Around 35% of semisynthetic facilities operate bioreactors exceeding 100,000-liter capacity per batch cycle. Nearly 18% of total global artemisinin output in 2024 was derived from continuous fermentation platforms operating 24-hour production schedules. Additionally, 26% of semisynthetic manufacturers integrated downstream purification systems capable of achieving 99% chemical purity within 48-hour processing timelines.

By Application

Based on application, the market is categorized into Antimalarial Injections and Antimalarial Tablets.

• Antimalarial Injections: Antimalarial injections represent 35% of the Artemisinin Market Share. Injectable artesunate is used in 85% of severe malaria hospital treatments. Around 40 million injectable doses are distributed annually. Hospitals account for 70% of injectable procurement. Nearly 60% of severe cases involve pediatric patients under 5 years. Shelf-life stability exceeds 24 months under controlled storage conditions. Approximately 48% of injectable formulations are supplied in 60 mg vial presentations for rapid intravenous administration. Around 33% of hospital procurement contracts specify cold-chain logistics maintaining storage between 2°C and 8°C. Nearly 27% of emergency malaria treatment centers reported a 15% increase in injectable demand during peak transmission seasons between 2023 and 2024.

• Antimalarial Tablets: Antimalarial tablets account for 65% share. Over 120 million ACT tablet courses are distributed annually. Approximately 58% of distributed doses target pediatric formulations. Rural clinics represent 68% of tablet-based distribution points. Tablet blister packaging improved moisture resistance by 35% over the past 5 years. More than 75% of national malaria programs rely primarily on oral ACT regimens. Nearly 42% of tablet formulations are supplied in fixed-dose combinations containing 2 active pharmaceutical ingredients in standardized 3-day treatment regimens. Around 36% of community health centers maintain buffer stock levels covering at least 6 months of projected malaria incidence. Additionally, 29% of newly introduced tablet SKUs between 2023 and 2025 incorporated dispersible formats with dissolution times below 3 minutes to enhance pediatric compliance rates above 80%.

MARKET DYNAMICS

Driving Factor

High Global Malaria Burden and ACT Treatment Protocols

More than 240 million malaria cases annually sustain continuous demand in the Artemisinin Market Growth cycle. Sub-Saharan Africa accounts for over 90% of malaria-related mortality, driving procurement of more than 100 million ACT courses yearly. Pediatric populations under 5 years represent nearly 80% of malaria deaths, emphasizing pediatric-focused dosing demand. Approximately 70% of treatment programs are financed by public or donor-backed funding mechanisms. Injectable artesunate is administered in over 85% of severe malaria cases admitted to hospitals. The Artemisinin Market Insights reveal that 60% of endemic countries mandate ACTs as first-line therapy under national treatment guidelines.

• Approximately 50% of global malaria-endemic countries have adopted ACTs as first-line treatment, significantly increasing artemisinin demand (according to WHO Malaria Report 2023).

• In Asia-Pacific, large-scale cultivation of Artemisia annua spans over 35,000 hectares, supplying raw material for pharmaceutical production (according to Food and Agriculture Organization, FAO).

Restraining Factor

Agricultural Dependency and Yield Volatility

Artemisinin extraction depends on Artemisia annua, with yields fluctuating between 0.5% and 1.5% artemisinin content per dry leaf weight. Approximately 43% of farmers report annual yield variability exceeding 20%. Climate variability affects 35% of cultivation areas annually. Around 60% of raw material production is concentrated in 2 to 3 countries, creating supply concentration risks. Price instability has resulted in supply-demand imbalances during 3 major cycles over the past decade. The Artemisinin Market Analysis identifies that 28% of procurement delays are linked to raw material shortages.

• Counterfeit and substandard anti-malarial drugs constitute around 20% of the market in Africa and Southeast Asia, limiting artemisinin adoption (according to United Nations Office on Drugs and Crime, UNODC).

• Supply chain constraints for raw Artemisia annua impact over 25% of global production capacity, slowing market growth (according to Global Fund to Fight AIDS, Tuberculosis, and Malaria).

Expansion into Oncology and Antiviral Research

Opportunity

More than 50 active research programs are investigating artemisinin derivatives for oncology applications, with 30% targeting breast and colorectal cancer studies. Laboratory studies indicate that artemisinin compounds demonstrate cytotoxic effects in concentrations below 10 µM in 40% of tested cell lines. Approximately 20% of biotechnology firms in infectious disease research have initiated artemisinin derivative evaluation programs. Semisynthetic production methods increased by 27% between 2023 and 2024, enabling scalable output. The Artemisinin Market Opportunities expand as 15+ universities globally conduct phase 1 or 2 clinical evaluations.

Emerging Artemisinin Resistance

Challenge

Artemisinin resistance markers have been identified in more than 6 countries in Southeast Asia. Approximately 20% of tested parasite samples in certain regions show delayed parasite clearance. Treatment failure rates exceeding 10% have been documented in specific localized outbreaks. Around 33% of global surveillance programs intensified resistance monitoring between 2023 and 2025. The Artemisinin Industry Analysis highlights that 25% of R&D budgets are now allocated toward resistance mitigation strategies, including new combination partner drugs.

• Download Free Sample to learn more about this report

•  

ARTEMISININ MARKET REGIONAL INSIGHTS

• North America

North America holds approximately 5% of the Artemisinin Market Size. The U.S. accounts for over 80% of regional consumption. Approximately 2,000 malaria cases are reported annually in the U.S., with 95% travel-related. Around 60% of hospital treatments involve injectable formulations. Canada represents 15% of regional consumption. Over 30% of artemisinin demand in North America is linked to clinical research programs. Approximately 20 biotechnology firms conduct derivative research. Nearly 40% of imports originate from Asia-Pacific producers. Regulatory oversight covers 100% of pharmaceutical imports under federal standards. Approximately 35% of artemisinin-based procurement in the region is directed toward emergency hospital stockpiles with minimum 12-month inventory requirements. Around 18 clinical-stage trials evaluating artemisinin derivatives are active across 10 U.S. research centers. Nearly 45% of federally funded tropical disease grants include allocation for ACT-related therapeutic studies and resistance surveillance programs.

• Europe

Europe represents 12% of formulation activity in the Artemisinin Market Analysis. Germany, France, and the UK contribute 55% of regional processing capacity. Approximately 25% of global semisynthetic research projects are based in Europe. Malaria cases in Europe remain below 10,000 annually, with 90% travel-related. Around 45% of European demand is related to international health aid procurement. Over 30 pharmaceutical companies formulate ACT products within the region. Approximately 50% of EU-funded tropical disease programs support ACT distribution. Nearly 28% of European-based manufacturers focus on fixed-dose combination tablet production for export to 40+ endemic countries. Around 22% of regional R&D budgets are allocated to improving stability profiles above 30°C storage conditions. Approximately 33% of humanitarian medical supply contracts issued between 2023 and 2025 include artemisinin-based therapies as part of essential medicine distribution lists.

• Asia-Pacific

Asia-Pacific controls 68% of global artemisinin production. China contributes 55% of extracted supply, while Vietnam adds 15%. India represents 12% of regional API formulation output. Approximately 120,000 hectares of Artemisia annua cultivation are located in China. Around 25 fermentation facilities operate in the region for semisynthetic output. Domestic malaria cases in Southeast Asia declined by 40% over 5 years, yet export volumes increased by 30%. Nearly 60% of global ACT exports originate from Asia-Pacific manufacturing hubs. Approximately 50 extraction plants across 6 provinces in China process more than 150 metric tons of artemisinin annually. Around 32% of regional production capacity is integrated with downstream tablet and injectable formulation units. Nearly 26% of newly approved pharmaceutical manufacturing licenses between 2023 and 2024 in the region included artemisinin API or ACT production capabilities.

• Middle East & Africa

Africa accounts for over 70% of global consumption. Sub-Saharan Africa reports more than 200 million malaria cases annually. Nigeria, Democratic Republic of Congo, and Uganda collectively represent 40% of malaria incidence. Approximately 85% of distributed ACT tablets are consumed in Africa. Local formulation capacity accounts for 20% of regional demand. Around 35 countries operate national malaria elimination programs. Injectable artesunate use increased by 22% in hospital settings between 2023 and 2024. Approximately 60% of international ACT procurement shipments are delivered to 10 high-burden African countries each year. Around 24% of regional pharmaceutical manufacturing facilities upgraded packaging lines to support blister packs with 24-dose formats between 2023 and 2025. Nearly 31% of malaria control budgets in endemic African nations are allocated specifically to artemisinin-based combination therapy procurement and distribution logistics.

List of Top Artemisinin Companies

• Sanofi (France)
• KPC Pharmaceuticals (China)
• Kerui Nanhai (China)
• Guangxi xiancaotang (China)
• Guilin Pharmaceutical (China)
• Natural Bio-Engineering (U.K.)
• BIONEXX (Madagascar)
• CAT KHANH (Thailand)
• Beepz (U.S.)
• Novanat Bioresource (China)

Top 2 Companies with Highest Market Share:

• Sanofi : holds approximately 18% global ACT formulation share with distribution in over 100 countries.

• KPC Pharmaceuticals : accounts for nearly 15% global artemisinin API production capacity exceeding 60 metric tons annually.

Investment Analysis and Opportunities

Global investments in the Artemisinin Market Opportunities increased by 29% in semisynthetic production facilities between 2023 and 2025. Approximately 40% of new capital allocation supports fermentation-based manufacturing. Over 20 countries expanded malaria elimination budgets by more than 15% during this period. Around 35% of procurement contracts span multi-year supply agreements exceeding 3 years. Biotechnology collaborations increased by 25%. Nearly 50% of R&D pipelines target resistance mitigation. African cultivation expansion projects added 15,000 hectares between 2023 and 2024. Public-private partnerships represent 45% of ongoing infrastructure upgrades.

Approximately 38% of institutional investors prioritized vertically integrated supply models covering cultivation, extraction, and formulation within a single operational framework. Nearly 22 new or upgraded extraction units were commissioned globally between 2023 and 2025, increasing installed processing capacity by more than 30 metric tons annually. In addition, 33% of long-term supply agreements signed during this period included price stabilization clauses to manage raw material volatility exceeding 20% across seasonal cycles.

New Product Development

New product development in the Artemisinin Market Trends includes improved pediatric dispersible tablets representing 32% of new launches. Injectable formulations with enhanced stability at temperatures up to 40°C increased by 28%. Combination therapies incorporating 2 or 3 partner drugs account for 70% of pipeline innovations. Over 15 phase 2 oncology trials investigate artemisinin derivatives. Modified-release tablets extend dosing intervals by 12 hours in 25% of experimental formulations. Approximately 30% of new products focus on resistance-prone regions. Packaging improvements reduced moisture ingress by 35%.

Nearly 27% of newly introduced ACT formulations achieved bioavailability enhancement of more than 18% compared to earlier versions under standardized testing conditions. Around 21% of manufacturers implemented child-resistant blister packs with 3-layer aluminum barriers to maintain stability beyond 24 months in tropical climates. Furthermore, 19% of pipeline candidates are evaluating fixed-dose combinations optimized for body weight categories below 15 kg, addressing over 60% of pediatric malaria case distribution in endemic regions.

Five Recent Developments (2023–2025)

• In 2023, Sanofi expanded ACT production capacity by 20% across 2 facilities.
• In 2024, KPC Pharmaceuticals increased artemisinin API output by 18%, reaching over 60 metric tons annually.
• In 2023, Guilin Pharmaceutical introduced heat-stable injectable artesunate tested at 40°C for 6 months.
• In 2025, BIONEXX expanded Artemisia annua cultivation by 5,000 hectares in East Africa.
• In 2024, Natural Bio-engineering implemented fermentation upgrades improving yield efficiency by 22%.

Report Coverage of Artemisinin Market

The Artemisinin Market Report covers 2 product types and 2 primary applications across more than 30 countries. The Artemisinin Industry Report evaluates over 200,000 hectares of cultivation data and more than 200 metric tons of annual production output. Nearly 70% of analysis focuses on ACT distribution channels in 85 endemic countries. The Artemisinin Market Research Report includes 50+ quantitative indicators, 20+ company profiles, and 5 years of resistance monitoring statistics. Over 60% of insights are dedicated to procurement frameworks, supply chain concentration, and formulation trends supporting Artemisinin Market Size, Market Share, Market Growth, Market Outlook, Market Insights, and Market Forecast for B2B stakeholders.

The study further analyzes more than 120 million annual ACT treatment courses distributed globally, segmented by tablet and injectable dosage forms across 4 therapeutic categories. It evaluates 10+ regulatory frameworks governing pharmaceutical imports and local manufacturing compliance in high-burden regions representing over 75% of global consumption. Additionally, the Artemisinin Market Analysis integrates 25+ pipeline developments, 15 clinical-stage derivative programs, and 8 regional resistance surveillance clusters to provide detailed Artemisinin Industry Analysis for procurement managers, API manufacturers, and global health agencies.